Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy.

被引：0
|
作者：
Schonlau, Elena
Mueller, David Christian
Vandekerkhove, Gillian
Murtha, Andrew
Bacon, Jack V. W.
Wells, Connor
Rostin, Kimia
Parimi, Sunil
Noonan, Krista
Basappa, Naveen S.
Ko, Jenny J.
Finch, Daygen L.
Alimohamed, Nimira S.
Bismar, Tarek A.
Nappi, Lucia
Annala, Matti
Bernales, Cecily Q.
Chi, Kim N.
Wyatt, Alexander William
Eigl, Bernhard J.
机构：
[1] BC Canc Vancouver Ctr, Dept Med Oncol, Vancouver, BC, Canada
[2] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC, Canada
[3] BC Canc Surrey Ctr, Dept Med Oncol, Surrey, BC, Canada
[4] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada
[5] BC Canc Abbotsford Ctr, Dept Med Oncol, Abbotsford, BC, Canada
[6] BC Canc Kelowna Ctr, Dept Med Oncol, Kelowna, BC, Canada
[7] Tom Baker Canc Clin, Dept Med Oncol, Calgary, AB, Canada
[8] Tampere Univ, Tampere, Finland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4577
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Combined circulating tumour cell (CTC) and circulating tumor DNA (ctDNA) analysis of blood from patients with pancreatic cancer
    Brady, Ged
    Rothwell, Dominic
    Ayub, Mahmood
    Smith, Nigel
    Mohan, Sumitra
    Chudziak, Jakub
    Aung, Kyaw
    Hubner, Richard
    Miller, Crispin
    Backen, Alison
    Leong, Hui Sun
    Gulati, Sakshi
    Kim, Chang Sik
    Lamarca, Angela
    McNamara, Mairead
    Valle, Juan
    Dive, Caroline
    CANCER RESEARCH, 2016, 76
  • [32] Liquid biopsy in the clinic prospective study of plasma circulating tumor DNA (ctDNA) next generation sequencing (NGS) in patients with advanced non-small cell lung cancers to match targeted therapy.
    Sabari, Joshua K.
    Ni, Ai
    Lee, Adrian
    Pavlakis, Nick
    Clarke, Stephen John
    Tandon, Nidhi
    Datta, Sutirtha
    DuBoff, Mariel A.
    Martinez, Andres
    Offin, Michael D.
    Isbell, James M.
    Rusch, Valerie W.
    Jones, David Randolph
    Henderson, Samantha
    Lim, Lee
    Raymond, Chris
    Li, Mark
    Riely, Gregory J.
    Rudin, Charles M.
    Li, Bob T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Use of Circulating Tumor DNA (ctDNA) for Early Molecular Detection of Breast Cancer Relapse in Patients with Triple-Negative Breast Cancer (TNBC)
    Bagegni, Nusayba A.
    Ademuyiwa, Foluso O.
    CURRENT BREAST CANCER REPORTS, 2023, 15 (04) : 356 - 363
  • [34] Use of Circulating Tumor DNA (ctDNA) for Early Molecular Detection of Breast Cancer Relapse in Patients with Triple-Negative Breast Cancer (TNBC)
    Nusayba A. Bagegni
    Foluso O. Ademuyiwa
    Current Breast Cancer Reports, 2023, 15 : 356 - 363
  • [35] Circulating tumor DNA (ctDNA) for response assessment in patients with anal cancer treated with definitive chemoradiation.
    Alvarez, Janet
    Cercek, Andrea
    Mohan, Natasha
    Cuaron, John J.
    Zinovoy, Melissa
    Reyngold, Marsha
    Yaeger, Rona
    Hajj, Carla
    Fanta, Corrine
    Wong, Charles
    Segal, Neil Howard
    Paty, Philip
    Crane, Christopher H.
    Garcia-Aguilar, Julio
    Weiser, Martin R.
    Smith, Jesse Joshua
    Tuli, Richard
    Romesser, Paul Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 1 - 1
  • [36] The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant
    Cohen, Stacey A. A.
    Kasi, Anup
    Hook, Nicole
    Krainock, Michael
    Budde, Griffin
    Malashevich, Allyson Koyen
    Meltzer, Jeffrey
    Jelsema, Russ
    Olshan, Perry
    Billings, Paul R. R.
    Aleshin, Alexey
    Poklepovic, Andrew S. S.
    CASE REPORTS IN OBSTETRICS AND GYNECOLOGY, 2022, 2022
  • [37] Assessing the Impact of Circulating Tumor DNA (ctDNA) in Patients With Colorectal Cancer: Separating Fact From Fiction
    Gabriel, Emmanuel
    Bagaria, Sanjay P.
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [38] Analysis of circulating tumor DNA (ctDNA) from the phase II BLC2001 trial of erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC) to identify markers of intrinsic resistance to fibroblast growth factor receptor (FGFR)-targeted therapy
    Siefker-Radtke, A. O.
    Loriot, Y.
    Necchi, A.
    Huddart, R. A.
    Burgess, E. F.
    Rezazadeh, A.
    O'Hagan, A.
    De Porre, P.
    Avadhani, A.
    Monga, M.
    Cherkas, Y.
    Moy, C. H.
    Santiago-Walker, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S584 - S584
  • [39] Clinical utility of circulating tumor DNA (ctDNA) in patients with early/resected biliary tract cancer (BTC)
    Yu, J.
    Mehta, R.
    Anaya, D.
    Denbo, J.
    Bridges, C.
    Manage, K.
    Tin, A.
    Aushev, V.
    Sharma, S.
    Jurdi, A.
    Liu, M.
    Kim, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S55 - S56
  • [40] Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC).
    Pusztai, Lajos
    Chung, Jon
    Young, Lauren
    Schrock, Alexa Betzig
    Hartmaier, Ryan
    Frampton, Garrett Michael
    Gay, Laurie M.
    Stephens, Phil
    Miller, Vincent A.
    Ali, Siraj Mahamed
    Ross, Jeffrey S.
    Vahdat, Linda T.
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345